Ivermectin has a long track record as an antiparasitic drug, and while it's not a miracle cure, its antiviral properties—especially against other single-stranded RNA viruses like Zika and Dengue—make it worth looking into. If it shows promise in lab settings for similar viruses, why not consider it for SARS-CoV-2? The virus isn’t that different from its relatives in the same family.

The real issue isn’t whether it *could* work—it’s about the quality of the research. Some studies are promising, others are flawed. We need more rigorous, well-designed trials to know for sure. Dismissing it outright without looking at the evidence is short-sighted. Science is about exploring possibilities, not shutting them down before we even try.

There’s always room for optimism when it comes to new treatments. Ivermectin’s potential shouldn’t be ignored just because some studies are inconclusive. Let’s keep an open mind and keep pushing for better answers.